{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:02:32Z","timestamp":1778281352103,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2004,9,21]],"date-time":"2004-09-21T00:00:00Z","timestamp":1095724800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1007\/s00198-004-1725-z","type":"journal-article","created":{"date-parts":[[2004,9,20]],"date-time":"2004-09-20T07:01:54Z","timestamp":1095663714000},"page":"468-474","source":"Crossref","is-referenced-by-count":112,"title":["Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women"],"prefix":"10.1007","volume":"16","author":[{"given":"Socrates E.","family":"Papapoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara A.","family":"Quandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uri A.","family":"Liberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc C.","family":"Hochberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desmond E.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,9,21]]},"reference":[{"key":"CR1","doi-asserted-by":"crossref","unstructured":"Riggs BL, Melton LJ 3rd (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17[5\u00a0Suppl]:505S\u2013511S","DOI":"10.1016\/8756-3282(95)00258-4"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","volume":"359","author":"Cummings","year":"2002","unstructured":"Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761\u20131767","journal-title":"Lancet"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC, et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118\u20134124","journal-title":"J Clin Endocrinol Metab"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1385\/JCD:1:4:395","volume":"1","author":"Guyatt","year":"1998","unstructured":"Guyatt GH (1998) Evidence-based management of patients with osteoporosis. J Clin Densitom 1:395\u2013402","journal-title":"J Clin Densitom"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1001\/jama.281.19.1836","volume":"281","author":"Guyatt","year":"1999","unstructured":"Guyatt GH, Sinclair J, Cook DJ, Glasziou P (1999) Users\u2019 guides to the medical literature: XVI. How to use a treatment recommendation. Evidence-Based Medicine Working Group and the Cochrane Applicability Methods Working Group. JAMA 281:1836\u20131843","journal-title":"JAMA"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","volume":"23","author":"Cranney","year":"2002","unstructured":"Cranney A, Wells G, Willan A, et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508\u2013516","journal-title":"Endocr Rev"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","volume":"9","author":"Pols","year":"1999","unstructured":"Pols HA, Felsenberg D, Hanley DA, et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461\u2013468","journal-title":"Osteoporos Int"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"742","DOI":"10.7326\/0003-4819-136-10-200205210-00009","volume":"136","author":"Greenspan","year":"2002","unstructured":"Greenspan SL, Schneider DL, McClung MR, et al (2002) Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 136:742\u2013746","journal-title":"Ann Intern Med"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Broll J, et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase\u00a0III Osteoporosis Treatment Study Group. N Engl J Med 333:1437\u20131443","journal-title":"N Engl J Med"},{"key":"CR12","unstructured":"Bonnick SL (1998) Investigation of postmenopausal osteoporosis: alendronate vs. calcium trial. Bone 23 [Suppl\u00a05]:S476"},{"key":"CR13","doi-asserted-by":"crossref","unstructured":"Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR (1993) Design of the Fracture Intervention Trial. Osteoporosis Int 3 [Suppl\u00a03]:S29\u201339","DOI":"10.1007\/BF01623005"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jbmr.5650100517","volume":"10","author":"Looker","year":"1995","unstructured":"Looker AC, Johnston CC Jr, Wahner HW, et al (1995) Prevalence of low femoral bone density in older U.S. women from NHANES\u00a0III. J Bone Miner Res 10:796\u2013802","journal-title":"J Bone Miner Res"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jama.1997.03540380073035","volume":"277","author":"Karpf","year":"1997","unstructured":"Karpf DB, Shapiro DR, Seeman E, et al (1997) Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA 277:1159\u20131164","journal-title":"JAMA"},{"key":"CR16","first-page":"265","volume":"82","author":"Bone","year":"1997","unstructured":"Bone HG, Downs RW Jr, Tucci JR, et al (1997) Dose\u2013response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab 82:265\u2013274","journal-title":"J Clin Endocrinol Metab"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","volume":"99","author":"Chesnut","year":"1995","unstructured":"Chesnut CH 3rd, McClung MR, Ensrud KE, et al (1995) Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144\u2013152","journal-title":"Am J Med"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S8756-3282(95)00262-6","volume":"17","author":"Adami","year":"1995","unstructured":"Adami S, Passeri M, Ortolani S, et al (1995) Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 17:383\u2013390","journal-title":"Bone"},{"key":"CR19","doi-asserted-by":"crossref","unstructured":"McCullagh P, Nelder JA (1989) Generalized linear models. Chapman and Hall, London","DOI":"10.1007\/978-1-4899-3242-6"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/sim.4780060306","volume":"6","author":"Peto","year":"1987","unstructured":"Peto R (1987) Why do we need systematic overviews of randomized trials? Stat Med 6:233\u2013244","journal-title":"Stat Med"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00198-002-1301-3","volume":"14","author":"Hauselmann","year":"2003","unstructured":"Hauselmann HJ, Rizzoli R (2003) A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 14:2\u201312","journal-title":"Osteoporos Int"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1210\/jcem.87.6.8575","volume":"87","author":"Bell","year":"2002","unstructured":"Bell NH, Bilezikian JP, Bone HG 3rd, Kaur A, Maragoto A, Santora AC for the MK-063 Study Group (2002) Alendronate increases bone mass and reduces bone markers in postmenopausal African\u2013American women. J Clin Endocrinol Metab 87:2792\u20132797","journal-title":"J Clin Endocrinol Metab"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S, et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604\u2013610","journal-title":"N Engl J Med"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-004-1725-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-004-1725-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-004-1725-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:03:50Z","timestamp":1558609430000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-004-1725-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,21]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["1725"],"URL":"https:\/\/doi.org\/10.1007\/s00198-004-1725-z","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9,21]]}}}